Zai Lab Limited announced that the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include both QINLOCK® (ripretinib) for advanced gastrointestinal stromal tumor (GIST) patients who have received prior treatment with three or more kinase inhibitors in the all-comer setting, and NUZYRA® (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) for intravenous (IV) formulation. In December 2021, NUZYRA was approved as a Category 1 innovative drug by the China National Medical Products Administration (NMPA) with both oral and IV formulations, for the treatment of CABP and ABSSSI. It is locally manufactured in China.

In March 2021, QINLOCK was approved by the NMPA for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. QINLOCK targets the broad spectrum of KIT and PDGFRa mutations known to drive GIST.